NCT03720288

Acetazolamide in Patients With Acute Heart Failure

Prospective Analysis Between Acetazolamide vs Placebo in Patients With Acute Heart Failure

• Status: Unknown
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 90 (estimated)
• Sponsor: University of Sao Paulo General Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Introduction: Recent studies have suggested that the use of acetazolamide may assist in the vol- ume management of patients with decompensated heart failure (HF). However, prospective and randomized comparison in patients with HF and optimized diuretic therapy has not been described. Objective: The aim of this study was to evaluate the effectiveness and safety of the use of acetazolamide versus placebo in volume control in patients with decompensated HF. Methodology: For this, a unicentric, randomized, double blind and prospective study will be performed in a comparative manner. Hospital data (test results, medical outcomes, drug dose, complications) of patients will be analyzed for safety and effectiveness. Expected results: The use of acetazolamide as an adjuvant treatment is superior to the standard strategy for volume control in patients with decompensated HF.

Conditions

• Heart Failure
• Acute Heart Failure

Interventions

Type	Name	Description
DRUG	Acetazolamide	Patient will follow the treatment according to inclusion sequence, receiving the corresponding number medication.
DRUG	Placebo	Patient will follow the treatment according to inclusion sequence, receiving the corresponding number medication.

Timeline

• Start date: 2018-10-01
• Primary completion: 2019-10-01
• Completion: 2020-10-01
• First posted: 2018-10-25
• Last updated: 2018-10-30

Locations

1 site across 1 country: Brazil